Real-World Impact of Low-Grade Toxicities to Adjuvant Pembrolizumab in Stage III Melanoma
JCO Oncology Practice · 2025
DOI: 10.1200/op-24-01013 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Nasreen Abdul Aziz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom. Hauptthemen laut MEDLINE: Melanoma, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Skin Neoplasms. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Primary malignant melanoma is a curable disease, with surgical resection being the gold standard of treatment. For stage III melanoma, which poses a high risk of recurrence, adjuvant checkpoint inhibitors are used to reduce the risk of relapse. However, adjuvant treatment carries a risk of immune-related adverse events that can significantly impact on quality of life. Although the impact of grade 3 to 4 toxicities has been well characterized, the impact of lower-grade toxicity in this setting has not been as robustly discussed in the literature. METHODS We gathered retrospective data on patients with stage III melanoma who underwent adjuvant pembrolizumab treatment between December 2019 and December 2022 from two sites (Belfast City Hospital and Royal Preston Hospital). This included information on toxicity on the basis of Common Terminology Criteria for Adverse Events grading (version 5), treatment discontinuation, hospital admission, toxicity treatments, and disease progression. RESULTS Data were collected on 142 patients. 67 (47%) completed a 1-year course of adjuvant pembrolizumab. Median recurrence-free survival was 36.2 months. One hundred (70%) experienced treatment-related toxicity, of whom 72 (51%) had only low-grade toxicity (grade 1 to 2). In patients with only low-grade toxicity, 15% were hospitalized, 31% had treatment stopped because of toxicity, and 33% required immunosuppression treatment. The rate of early treatment discontinuation was higher among patients age 65 years or older compared with patients younger than 65 years (66% v 38%, P < .001). CONCLUSION In addition to the impact of grade 3 to 4 toxicities, there is a substantial burden of low-grade toxicity in patients undergoing adjuvant pembrolizumab treatment for stage III melanoma. Clinicians should discuss its potentially significant impact with patients and prepare to support them through these effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, United Kingdom.
- Department of Medical Oncology, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, United Kingdom.
ORCID-Profile: Nasreen Abdul Aziz, David Burke, Sharanniyan Ragavan, Olabode Oladipo
Zitieren
APA
Abdul Aziz, N., Burke, D., Khalifa, W., Ragavan, S., Board, R., & Oladipo, O. (2025). Real-World Impact of Low-Grade Toxicities to Adjuvant Pembrolizumab in Stage III Melanoma. JCO Oncology Practice. https://doi.org/10.1200/op-24-01013
Vancouver
Abdul Aziz N, Burke D, Khalifa W, Ragavan S, Board R, Oladipo O. Real-World Impact of Low-Grade Toxicities to Adjuvant Pembrolizumab in Stage III Melanoma. JCO Oncology Practice. 2025. doi:10.1200/op-24-01013
BibTeX
@article{AbdulAziz2025,
author = {Abdul Aziz, Nasreen and Burke, David and Khalifa, Waleed and Ragavan, Sharanniyan and Board, Ruth and Oladipo, Olabode},
title = {Real-World Impact of Low-Grade Toxicities to Adjuvant Pembrolizumab in Stage III Melanoma},
journal = {JCO Oncology Practice},
year = {2025},
doi = {10.1200/op-24-01013}
}
EUVIMED